Recent Updates
Recently added Catalysts
OSUR

Ronald H. Spair Shauna White Chief Financial Officer Corporate Marketing Manager 610-882-1820 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com ORASURE TECHNOLOGIES

Key Takeaway: Ronald H. Spair Shauna White Chief Financial Officer Corporate Marketing Manager 610-882-1820 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com ORASURE TECHNOLOGIES ANNOUNCES SETTLEMENT OF LITIGATION WITH PA Februar

Full Press Release Details

Ronald H. Spair Shauna White
Chief Financial Officer Corporate Marketing Manager
610-882-1820 484-353-1575
Investorinfo@orasure.com media@orasure.com
www.orasure.com www.orasure.com
ORASURE TECHNOLOGIES ANNOUNCES SETTLEMENT OF LITIGATION WITH
PA February 6, 2017 OraSure Technologies, Inc. (NASDAQ: OSUR) today announced the settlement of litigation for patent infringement and breach of contract filed by its subsidiary, DNA Genotek, Inc. ( DNA
Genotek ), against Ancestry.comDNA LLC ( Ancestry ) and Spectrum Solutions LLC ( Spectrum ), Ancestry s contract manufacturer.
Under a Settlement and License Agreement executed by the parties, Ancestry has agreed to pay DNA Genotek a settlement fee of $12.5 million. In addition, DNA
Genotek has granted Ancestry a royalty-bearing, non-exclusive, worldwide license to certain patents and patent applications related to the collection of DNA in human saliva. The license granted to Ancestry is limited to saliva DNA collection kits
sold or used as part of Ancestry s genetic testing service offerings and does not cover the sale or use of product outside of Ancestry s business. The Settlement and License Agreement also provides DNA Genotek with a royalty-free,
non-exclusive license to patents related to Ancestry s existing saliva DNA collection kit and certain modifications thereto.
The parties have each
agreed to a mutual release of claims and other provisions typical for settlement agreements of this type. The Agreement provides for the dismissal of pending federal lawsuits in the District of Delaware and the Southern District of California and
for the parties to jointly seek termination of Inter Partes Review proceedings before the U.S. Patent and Trademark Office involving the DNA Genotek patents asserted in the litigation.
We are pleased to have resolved this litigation, said Douglas A. Michels, President and CEO of DNA Genotek s parent company, OraSure
Technologies, Inc. We are committed to innovation and the creation of new products and solutions for customers in the markets that we serve. An important part of this commitment is the protection of our technology and products and we will
remain vigilant in seeking to enforce our intellectual property rights where needed.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture and distribution of point-of-care diagnostic and collection devices and other technologies
designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick
platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure s portfolio of products is sold globally to
various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians offices, commercial and industrial
entities and consumers. The Company s products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. For more information on OraSure Technologies, please
Genotek Inc., a subsidiary of OraSure Technologies, Inc., focuses on providing high-quality biological sample collection products and end-to-end services for human genomics, microbiome and infectious disease applications. The Company s Oragene Dx and ORAcollect Dx product lines are the first and only FDA 510(k) cleared saliva-based DNA collection devices for in vitro
diagnostic use. DNA Genotek also offers Research Use Only products to collect and preserve large amounts of DNA or RNA from multiple sample types. DNA Genotek markets its products worldwide and has a global customer base with thousands of customers
in over 100 countries. For more information about DNA Genotek, visit www.dnagenotek.com.
Last updated: Feb 6, 2017